secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allakos Inc. (—)
CIK:        0001564824
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056902
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allakos Q1 net loss $71.1M ($0.81/sh); cash burn $31.5M; impairment $27.3M
--------------------------------------------------------------------------

- Net loss $71.1M vs $42.4M YoY; diluted EPS $(0.81) vs $(0.49); non-cash impairment charge $27.3M from lirentelimab halt.
- Cash, equivalents, investments $139.3M at March 31; net decrease $31.5M in Q1; runway extended into mid-2026.
- Restructuring costs for lirentelimab closeout ~$30M total; $12M paid in Q1, remaining ~$18M expected Q2-Q3 2024.
- Completed Phase 1 dosing of AK006 (IV and SC) in healthy volunteers; initiated Phase 1 trial in chronic spontaneous urticaria.
- Upcoming milestones: Phase 1 healthy volunteer data Q2/Q3 2024; CSU topline data year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/0000950170-24-056902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/allk-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer